PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1573935
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1573935
HPV Associated Disorders Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global HPV Associated Disorders Treatment Market, witnessed at USD 19.6 billion in 2023, will demonstrate a 4.9% CAGR between 2024 and 2032, spurred by the rising prevalence of HPV-related cancers, coupled with advancements in diagnostic technologies. As awareness of the link between HPV and various cancers increases, more individuals seek testing and treatment options. Innovations in diagnostic tools enhance the accuracy and speed of HPV detection, allowing for earlier interventions. This growing focus on prevention and effective management of HPV-related disorders is likely to boost the demand for targeted therapies and screening programs, further propelling market growth.
The HPV associated disorders treatment industry disease type, treatment type, end-use, and region.
The cervical intraepithelial neoplasia (CIN) segment achieved USD 6.1 billion in 2023, fueled by the high prevalence of HPV infections leading to CIN. As awareness of the condition grows, there is an increasing demand for effective screening and treatment options. Advances in diagnostic technologies allow for earlier detection and intervention, improving patient outcomes. Additionally, the availability of targeted therapies and preventive measures, such as vaccines, further enhances the focus on managing CIN, solidifying its dominant position in the market.
The medication segment secured 68.3% in 2023, primarily due to the increasing availability of effective antiviral therapies and treatments for HPV-related conditions. As awareness of HPV's impact on health grows, patients are seeking medical solutions to manage and treat associated disorders. Innovations in pharmaceutical formulations, including targeted therapies and immunotherapies, enhance treatment efficacy. Furthermore, the ongoing development of new medications and combination therapies will drive market growth, solidifying the medication segment's prominent position.
North America will grow at 4.5% CAGR to reach USD 13.3 billion by 2032, driven by high awareness of HPV-related health issues and robust healthcare infrastructure. The region benefits from advanced diagnostic technologies and a wide range of treatment options, including vaccines and medications. Public health initiatives aimed at increasing vaccination rates and early detection further support market growth. Also, significant investments in research and development for innovative therapies contribute to a thriving market environment, making North America a key contributor to the overall expansion of HPV treatment options.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of HPV infections
- 3.2.1.2 Technological advancements in diagnostics
- 3.2.1.3 Rising awareness and education
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of vaccines and treatments
- 3.2.2.2 Side effects and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Future market trends
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Cervical intraepithelial neoplasia (CIN)
- 5.3 Cervical cancer
- 5.4 Anal intraepithelial neoplasia (AIN)
- 5.5 Anal cancer
- 5.6 Genital warts
- 5.7 Other disease types
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Medication
- 6.2.1 Vaccines
- 6.2.2 Anti-viral drugs
- 6.2.3 Other medications
- 6.3 Surgery
- 6.3.1 Cryotherapy
- 6.3.2 Laser surgery
- 6.3.3 Other surgery types
Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Ambulatory surgical centers
- 7.4 Specialty clinics
- 7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Biocon Ltd.
- 9.2 Bristol-Myers Squibb Company
- 9.3 Cleveland Clinic
- 9.4 Eli Lilly and Company
- 9.5 F. Hoffmann-La Roche AG
- 9.6 GlaxoSmithKline plc
- 9.7 Hologic, Inc.
- 9.8 INOVIO Pharmaceuticals
- 9.9 Johnson and Johnson Services Inc. (Janssen Pharmaceutical)
- 9.10 Mayo Foundation for Medical Education and Research (MFMER).
- 9.11 Memorial Sloan Kettering Cancer Center
- 9.12 Merck and Co., Inc.
- 9.13 Pfizer, Inc.
- 9.14 The Johns Hopkins Hospital
- 9.15 Thermo Fisher Scientific Inc.
